Diltiazem
Diltiazem is in a group of drugs called calcium channel blockers. It works by relaxing the muscles of your heart and blood vessels.
| Product dosage: 180mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $3.37 | $101.00 (0%) | 🛒 Add to cart |
| 60 | $2.70 | $202.00 $162.00 (20%) | 🛒 Add to cart |
| 90 | $2.49 | $303.00 $224.00 (26%) | 🛒 Add to cart |
| 120 | $2.37 | $404.00 $284.00 (30%) | 🛒 Add to cart |
| 180 | $2.26 | $606.00 $406.00 (33%) | 🛒 Add to cart |
| 270 | $2.19
Best per pill | $909.00 $590.00 (35%) | 🛒 Add to cart |
| Product dosage: 60mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.82 | $49.00 (0%) | 🛒 Add to cart |
| 90 | $0.78 | $73.50 $70.00 (5%) | 🛒 Add to cart |
| 120 | $0.76 | $98.00 $91.00 (7%) | 🛒 Add to cart |
| 180 | $0.73 | $147.00 $132.00 (10%) | 🛒 Add to cart |
| 270 | $0.72 | $220.50 $195.00 (12%) | 🛒 Add to cart |
| 360 | $0.71
Best per pill | $294.00 $257.00 (13%) | 🛒 Add to cart |
Similar products
More info:
Nimotop: Targeted Cerebral Vasospasm Protection Post-SAH
Nimotop (nimodipine) is a calcium channel blocker specifically formulated for the improvement of neurological outcomes by reducing the incidence and severity of ischemic deficits in patients with subarachnoid hemorrhage (SAH) from ruptured congenital intracranial aneurysms. Its cerebroselective mechanism targets cerebral arteries, offering a critical neuroprotective strategy during a vulnerable clinical period. Administered orally, it represents a cornerstone of post-SAH medical management, supported by extensive clinical evidence demonstrating its efficacy in preserving cognitive and motor function when initiated within 96 hours of the hemorrhage.
Onglyza: Advanced DPP-4 Inhibitor for Type 2 Diabetes Management
Onglyza (saxagliptin) is a prescription medication designed to improve glycemic control in adults with type 2 diabetes mellitus. As a dipeptidyl peptidase-4 (DPP-4) inhibitor, it works by enhancing the body’s natural ability to lower blood sugar when it is elevated. This medication is typically used in combination with diet and exercise, and may be prescribed alongside other antidiabetic agents such as metformin, sulfonylureas, or thiazolidinediones. Onglyza offers a targeted mechanism of action that supports sustained glucose management without causing weight gain in most patients.
Pletal: Advanced Peripheral Artery Disease Symptom Relief
Pletal (cilostazol) is a quinolinone-derived phosphodiesterase III inhibitor specifically indicated for the reduction of symptoms of intermittent claudication, a manifestation of peripheral artery disease. This vasodilatory and antiplatelet agent works through dual mechanisms of action to improve microcirculatory blood flow and increase pain-free walking distance. It represents a cornerstone of pharmacologic management for patients whose symptoms are not adequately controlled by exercise and lifestyle modification alone. Clinical efficacy is well-established through multiple randomized controlled trials demonstrating significant functional improvement.
Actoplus Met: Dual-Action Control for Type 2 Diabetes
Actoplus Met combines two proven antihyperglycemic agents, pioglitazone and metformin, into a single tablet to provide comprehensive glycemic management for adults with type 2 diabetes mellitus. This fixed-dose combination therapy targets two key pathophysiological defects of the disease—insulin resistance and hepatic glucose overproduction—offering a synergistic approach to lower both fasting and postprandial blood glucose levels. By addressing multiple mechanisms simultaneously, it can simplify treatment regimens and improve adherence, which is critical for long-term metabolic control and reducing the risk of diabetes-related complications.
Actos: Advanced Type 2 Diabetes Management with Pioglitazone
Actos (pioglitazone hydrochloride) is a thiazolidinedione-class oral antidiabetic agent indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. By enhancing insulin sensitivity in peripheral tissues, it addresses core pathophysiological defects associated with the disease. This medication is designed for long-term management, helping to stabilize blood glucose levels and potentially reduce the risk of diabetic complications when used as part of a comprehensive treatment plan under medical supervision.
Amaryl: Advanced Glycemic Control for Type 2 Diabetes
Amaryl (glimepiride) is a second-generation sulfonylurea oral antidiabetic agent indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It functions primarily by stimulating insulin secretion from the pancreatic beta cells. This medication is recognized for its once-daily dosing convenience and its role in comprehensive diabetes management strategies, often used both as monotherapy and in combination with other antihyperglycemic agents when needed.
Baclofen: Effective Muscle Spasticity Relief for Enhanced Mobility
Baclofen is a centrally-acting skeletal muscle relaxant primarily indicated for the management of muscle spasticity. It functions as a gamma-aminobutyric acid (GABA) derivative, specifically targeting GABA-B receptors within the spinal cord to inhibit monosynaptic and polysynaptic reflex transmission. This pharmacological action results in reduced muscle tone and frequency of spasms, offering significant symptomatic relief for patients with neurological conditions. Clinicians value baclofen for its targeted mechanism and well-established efficacy profile in both oral and intrathecal formulations.
Baclosign: Targeted Spasticity Relief with Precision Muscle Relaxation
Baclosign (baclofen) is a centrally acting skeletal muscle relaxant specifically formulated for the management of spasticity resulting from multiple sclerosis, spinal cord injuries, and other neurological diseases. It operates as a gamma-aminobutyric acid (GABA) agonist, primarily exerting its effect at the spinal cord level to inhibit monosynaptic and polysynaptic reflex transmission. This targeted mechanism reduces the frequency and amplitude of muscle spasms, alleviates associated pain, and improves range of motion, thereby facilitating daily activities and therapeutic regimens.
Colospa: Targeted Relief for Irritable Bowel Syndrome Discomfort
Colospa (mebeverine hydrochloride) is an antispasmodic agent specifically formulated for the symptomatic management of Irritable Bowel Syndrome (IBS). It functions as a direct smooth muscle relaxant, acting predominantly on the gastrointestinal tract to alleviate spasmodic pain and cramping without affecting normal gut motility. By targeting the underlying muscle hyperactivity responsible for discomfort, Colospa provides focused relief, helping to restore daily comfort and function for individuals affected by IBS. Its selective action minimizes systemic side effects, making it a well-tolerated option for long-term symptom control.